Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited product differentiation. Recent Phase 3 results for elegrobart (VRDN-003) and ...
argenx SE retains a Hold rating due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Recent termination of TED and lupus nephritis programs narrows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results